NDA 019860 · Kenvue Brands
Imodium A-D
Loperamide Hydrochloride · Oral
Last checked: Nov 20, 2026Latest source record: Mar 7, 2019 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1989
Nov 22, 1989
Approved uses
1
Original approval plus efficacy supplements
Registered trials
97
20 Phase 3, 11 recruiting
FAERS reports
44,941
27,585 serious, 3,911 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Nov 22, 1989 Original approval · Type 3 - New Dosage Form
1 products under this application
- IMODIUM A-D · LOPERAMIDE HYDROCHLORIDE 2MG · TABLET, ORAL · Over-the-counter
Clinical trials
Interventional ClinicalTrials.gov studies with "Loperamide" as an intervention, any sponsor and status, largest first.
Puma Biotechnology, Inc.Industry
NCT02400476 · 563 participants · Start Feb 2015 · Primary completion Apr 22, 2021
Drug: Neratinib; Loperamide and 2 more · For: Early Stage HER2+ Breast Cancer
Sites: Birmingham, Alabama; Corona, California; Fullerton, California · 58 sites in all
- Octreotide Compared With Loperamide Hydrochloride for Chemotherapy-Related Diarrhea in Patients With Colorectal CancerPivotal-lookingCompleted
Eastern Cooperative Oncology GroupResearch network
NCT00003057 · 500 participants (planned) · Start Mar 26, 1997 · Primary completion May 2000
Drug: loperamide hydrochloride; octreotide acetate · For: Colorectal Cancer; Diarrhea
Sites: La Jolla, California; San Francisco, California; Wilmington, Delaware · 33 sites in all
- Prevention and Treatment of Pyrrolitinib-associated DiarrheaPivotal-lookingStatus unknown
Tianjin Medical University Cancer Institute and HospitalAcademic, hospital or other
NCT04736186 · 470 participants (planned) · Start May 16, 2020 · Primary completion Oct 31, 2022
Drug: Loperamide; Loperamide and golden bifid and 1 more · For: Breast Cancer
Sites: Tianjin, China
- Acupuncture for Patients With Diarrhea-predominant IBS or Functional Diarrhea: a Randomized Controlled TrialPivotal-lookingCompleted
Chengdu University of Traditional Chinese MedicineAcademic, hospital or other
NCT01350570 · 449 participants · Start Aug 2011 · Primary completion Feb 2014
Drug: Loperamide · For: Diarrhea-predominant Irritable Bowel Syndrome; Functional Diarrhea
Sites: Chengdu, China
BeOne MedicinesBeOne Medicines (BeiGene) (ONC)
NCT06120283 · 433 participants (planned) · Start Dec 1, 2023 · Primary completion Dec 2029
Drug: BGB-43395; Fulvestrant and 3 more · For: Advanced Solid Tumor; Advanced Breast Cancer; Metastatic Breast Cancer and 5 more
Sites: Denver, Colorado; Lake Mary, Florida; Detroit, Michigan · 61 sites in all
- A Comparison of Three Medications to Treat Diarrhea in Adults.Pivotal-lookingCompleted
McNeil ABIndustry
NCT00807326 · 415 participants · Start Nov 2008 · Primary completion Aug 2009
Drug: Loperamide/simeticone 2 mg/125 mg caplets; Loperamide/simeticone 2 mg/125 mg chewable tablets and 1 more · For: Diarrhea
Sites: Mormugao, India; San José del Cabo, Mexico; San Miguel de Allende, Mexico · 6 sites in all
- Trial Evaluating Ambulatory Treatment of Travelers' DiarrheaPivotal-lookingTerminated
Uniformed Services University of the Health SciencesFederal agency
NCT01618591 · 384 participants · Start Sep 2012 · Primary completion Mar 2016
Drug: Single dose rifaximin 1650 mg; Single dose azithromycin 500 mg and 3 more · For: Acute Watery Diarrhea; Dysentery/Febrile Diarrhea
Sites: Camp Bastion Air Base, Afghanistan; Camp Lemonnier, Djibouti; Soto Cano Air Base, Honduras · 5 sites in all
- Antibiotics and Vaccine Immune Responses StudyPivotal-lookingRecruiting
South Australian Health and Medical Research InstituteAcademic, hospital or other
NCT06148025 · 348 participants (planned) · Start Nov 23, 2023 · Primary completion Oct 1, 2027
Drug: BCG vaccine; Yellow Fever vaccine and 4 more · For: Vaccine Response Impaired
Sites: Adelaide, Australia
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- diarrhoea8,976
- nausea4,323
- drug ineffective4,099
- fatigue3,916
- off label use3,251
- vomiting2,788
- constipation2,503
- weight decreased2,103
- headache2,046
- dyspnoea2,020
- decreased appetite1,843
- asthenia1,839
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 355 |
| 2005 | 383 |
| 2006 | 393 |
| 2007 | 439 |
| 2008 | 529 |
| 2009 | 595 |
| 2010 | 639 |
| 2011 | 654 |
| 2012 | 1,057 |
| 2013 | 948 |
| 2014 | 1,140 |
| 2015 | 3,461 |
| 2016 | 2,284 |
| 2017 | 3,131 |
| 2018 | 3,200 |
| 2019 | 3,186 |
| 2020 | 3,123 |
| 2021 | 2,864 |
| 2022 | 3,372 |
| 2023 | 3,683 |
| 2024 | 3,569 |
| 2025 | 3,540 |
| 2026 | 2,393 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Clinical management of high-output stoma: a systematic literature review and meta-analysis.
Lederhuber H, Massey LH, Kantola VE, et al. · Tech Coloproctol 2023 · Systematic Review, Meta-Analysis
- Stool form scale as a useful guide to intestinal transit time.
Lewis SJ, Heaton KW · Scand J Gastroenterol 1997 · Clinical Trial, Randomized Controlled Trial
- Interactions between herbal medicines and prescribed drugs: an updated systematic review.
Izzo AA, Ernst E · Drugs 2009 · Systematic Review
- Loperamide (imodium)--clinical trial.
Dzieniszewski J, Ciok J, Jarosz M · Ther Hung 1990 · Clinical Trial
- Irritable bowel syndrome.
Ford AC, Vandvik PO · BMJ Clin Evid 2010 · Systematic Review
- Irritable bowel syndrome.
Ford AC, Vandvik PO · BMJ Clin Evid 2012 · Systematic Review
Sponsor: Kenvue Brands
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.